Evidence method
Level · gp.fundamentals.debt_to_revenue
41.73% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
WST · Jun 30, 2019
WEST PHARMACEUTICAL SERVICES INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000105770-19-000033General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
6.03% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
22.38% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.shares_outstanding
0.29% · CORE · VALID
Evidence method
Yoy · gp.fundamentals.revenue
4.96% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
49.46% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
33.62% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
17.14% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
2.04% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
1.53% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History39 statesSelf-history eligible
Mar 31, 201910/10 normalizedLevel 3Jun 30, 201910/10 normalizedLevel 3Sep 30, 201910/10 normalizedLevel 3Dec 31, 20198/8 normalizedLevel 3Mar 31, 20209/9 normalizedLevel 3Jun 30, 20209/9 normalizedLevel 3Sep 30, 20209/9 normalizedLevel 3Dec 31, 20209/9 normalizedLevel 3Mar 31, 20219/9 normalizedLevel 3Jun 30, 20219/9 normalizedLevel 3Sep 30, 20219/9 normalizedLevel 3Dec 31, 20219/9 normalizedLevel 3Mar 31, 20229/9 normalizedLevel 3Jun 30, 20229/9 normalizedLevel 3Sep 30, 20229/9 normalizedLevel 3Dec 31, 20229/9 normalizedLevel 3Mar 31, 20239/9 normalizedLevel 3Jun 30, 20239/9 normalizedLevel 3Sep 30, 20239/9 normalizedLevel 3Sep 30, 20269/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 44.08%
- Current
- 41.73%
- Delta
- -2.35%
- Previous
- 6.49%
- Current
- 6.03%
- Delta
- -0.47%
- Previous
- 10.73%
- Current
- 22.38%
- Delta
- 11.64%
- Previous
- -0.13%
- Current
- 0.29%
- Delta
- 0.41%
- Previous
- 6.69%
- Current
- 4.96%
- Delta
- -1.73%
- Previous
- 50.98%
- Current
- 49.46%
- Delta
- -1.52%
- Previous
- 33.10%
- Current
- 33.62%
- Delta
- 0.52%
- Previous
- 15.94%
- Current
- 17.14%
- Delta
- 1.20%
- Previous
- 2.21%
- Current
- 2.04%
- Delta
- -0.17%
- Previous
- 1.40%
- Current
- 1.53%
- Delta
- 0.13%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · WST Fundamental State →Has State · WEST PHARMACEUTICAL SERVICES INC →Transitioned To · WST Fundamental State →Transitioned To · WST BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · WST CAPEX_INTENSITY_DECREASED →Transitioned To · WST CASH_GENERATION_INCREASED →Transitioned To · WST DILUTION_INCREASED →Transitioned To · WST GROWTH_DECREASED →Transitioned To · WST INVENTORY_PRESSURE_DECREASED →Transitioned To · WST MARGIN_INCREASED →Transitioned To · WST PROFITABILITY_INCREASED →Transitioned To · WST R_AND_D_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.